MXPA00007102A - Skin and hair darkening composition - Google Patents
Skin and hair darkening compositionInfo
- Publication number
- MXPA00007102A MXPA00007102A MXPA/A/2000/007102A MXPA00007102A MXPA00007102A MX PA00007102 A MXPA00007102 A MX PA00007102A MX PA00007102 A MXPA00007102 A MX PA00007102A MX PA00007102 A MXPA00007102 A MX PA00007102A
- Authority
- MX
- Mexico
- Prior art keywords
- skin
- hair
- composition according
- cosmetic composition
- peptide
- Prior art date
Links
- 210000003491 Skin Anatomy 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 239000002537 cosmetic Substances 0.000 claims abstract description 16
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 235000001014 amino acid Nutrition 0.000 claims description 11
- 230000002209 hydrophobic Effects 0.000 claims description 5
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- 239000000693 micelle Substances 0.000 claims description 3
- 229960000310 ISOLEUCINE Drugs 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- 229960005190 Phenylalanine Drugs 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 claims 1
- 230000000699 topical Effects 0.000 abstract 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000005755 formation reaction Methods 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 7
- 108010039918 Polylysine Proteins 0.000 description 6
- 229920000656 polylysine Polymers 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000002780 Melanosomes Anatomy 0.000 description 5
- 229940120503 Dihydroxyacetone Drugs 0.000 description 4
- RXKJFZQQPQGTFL-UHFFFAOYSA-N Dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 102000003425 EC 1.14.18.1 Human genes 0.000 description 3
- 108060008724 EC 1.14.18.1 Proteins 0.000 description 3
- 210000002510 Keratinocytes Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 3
- 108010011110 polyarginine Proteins 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N 3-hydroxy-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- 210000000245 Forearm Anatomy 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 235000020127 ayran Nutrition 0.000 description 2
- 210000004027 cells Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000008278 cosmetic cream Substances 0.000 description 2
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible Effects 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229940108925 Copper Gluconate Drugs 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229940039717 Lanolin Drugs 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 210000002752 Melanocytes Anatomy 0.000 description 1
- RQPKNXVVIBYOBX-WDBKTSHHSA-N O=C(O)C(N)CC1=CC=C(O)C(O)=C1.ON([C@@H](CC1=CC=CC=C1)C(=O)O)O Chemical compound O=C(O)C(N)CC1=CC=C(O)C(O)=C1.ON([C@@H](CC1=CC=CC=C1)C(=O)O)O RQPKNXVVIBYOBX-WDBKTSHHSA-N 0.000 description 1
- 210000003463 Organelles Anatomy 0.000 description 1
- 206010062080 Pigmentation disease Diseases 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 229960000278 Theophylline Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N dopa Chemical compound OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003020 moisturizing Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000006128 skin development Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Abstract
A cosmetic skin/hair darkening composition for topical application to skin and/or hair is provided that comprises from 0.1 to 10%by weight of a peptide having an isoelectric point ranging from 6 to 11.
Description
COMPOSITION FOR DARING SKIN AND HAIR DESCRIPTION OF THE INVENTION The present invention relates to a cosmetic composition for darkening of the skin and / or hair. The invention also relates to a method for locally applying to the skin and / or hair a composition for darkening the skin / hair according to the invention. Tanning the skin by exposure to UV rays is a well-known phenomenon. However, it is also well known from the literature that such exposure to UV radiation results in accelerated skin development and increases the incidence of skin cancer. Consequently, alternative ways of tanning the skin have been developed. It is currently known in the art to use dihydr oxyacetone (DHA) as an aid for tanning not induced by UV rays. However, undesirably, the use of dihydroxy to cetane for purposes of tanning the skin rather produces an appearance of unnatural tanning. In addition, the artificial tan produced by DHA does not protect against UV radiation as a natural tan would.
Melanin is the black pigment of hair and skin and is synthesized from the amino acid tyrosine by melanosomes. Melanosomes are organelles found in melanocytes, a type of cell present at the confluence of rmi s - ep i e mi s. The enzyme thryokinase acts on tyrosine which is the main stage in melanogenesis. In melanosomes melanin is synthesized from monomers and transferred to neighboring cells called keratinocytes. The keratinocytes divide and differentiate and thus transport the melanosome to the surface of the skin. The intensity of skin color is directly related to the number, size, melanin content, speed of formation and migration / transfer of melanosomes to keratinocytes. Various specific sequences of amyloid and peptide residues are known to inhibit melanin pigmentation and have a bleaching effect on the skin (JP 6345797, JP 6321757, JP 6321755, JP 5170636, US 5,126,327). The peptides described in the prior art comprise a high proportion of basic and hydrophobic amino acids and have isoelectric point (pl) values greater than 5.5. These are mainly used to clarify the hyperpigmented areas associated with abnormal skin conditions. Applicants in their co-pending British patent application 9719195.1, describe a cosmetic composition for skin lightening comprising from 0.1 to 10% by weight of peptide with an isoelectric point of between 2 and 5.5. the isoelectric point (pl) is defined as the pH at which the net charge on a molecule is zero. Peptides that have a large number of acidic amino acids such as glutamic acid, aspartic acid, etc., have a low pl and those that have basic amino acids such as lysine, arginine, histidine, have a high pl. Applicants have found that a composition comprising peptide sequences having an isoelectric point (pl) of between 6 and 11 are capable of obscuring the skin / hair. Accordingly, the present invention relates to a cosmetic skin / hair darkening composition comprising from 0.1% to 10% by weight of a peptide with an isoelectric point (pl) ranging from 6.0 to 11.
The skin / hair darkening effected by the composition of the invention is reversible and without any side effects. The composition according to the invention is activated during the day and night. The peptide is a sequence of amino acids and is of a molecular weight ranging from 200 to 20,000 daltons (Da) with a pl ranging from 6.0 to 11.0. The peptide also optionally binds to a hydrophobic amino acid or to a target molecule or vehicle. The amino acid residues that form the peptide sequence can be presented naturally or synthetically, in the dextro or levo form, and include any derivative thereof. The peptide sequence must comprise a ratio of 1 basic amino acids such that the resulting peptide is basic in nature. The peptide sequence may be straight chain or cyclic. The molecular weight of the peptide sequence varies from 200 to 20,000 Da and preferably from 200 to 2000 Da. The pl of the peptide sequence varies from 6.0 to 11.0.
The hydrophobic amino acid can be selected from either alanine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan or valine and is preferably tryptophan. The target molecule is preferably a peptide and more preferably a hexapeptide which preferably has the primary sequence aspargine-glutamine-proline-leucine-1 eu-cyanide, and is located within the 27 amino acid residue from the carboxy terminus of the active peptide. Target vehicles such as micelle-and / or inverted micelles can also be used. According to a preferred aspect of the invention there is provided a cosmetic darkening composition for skin / hair comprising 0.5 to 5.0% by weight of the peptide. The invention further relates to a cosmetic method of darkening the skin / hair comprising the local application to the skin and / or hair of a composition according to the invention. The composition may also comprise a skin bronzing agent. This bronzing agent can be chosen from any known agent for this purpose such as dihydroxy acetone, theophylline, copper gluconate, natural active ingredients obtained from P t e r a n c t s a n t a l i n u s, and any other skin tanning agents. The composition according to the invention may also comprise a cosmetically compatible carrier. They may also comprise preservatives, emulsifiers, thickeners, perfume, color, skin benefit materials such as moisturizing emulsions, emollients and a n t i in ve j e c im e n t o. The vehicle which forms part of the cosmetic composition is one or more substances which are compatible with the sequence of po 1 i ami n or a c i do and which is also cosmetically acceptable in that it will not damage the skin / hair. The vehicles that can be used in the composition according to the invention can include absorbent powders, binders, and carriers, and liquids such as emollients, propellants, solvents, humectants and thickeners. Simple carriers such as alcohol, PEG, propylene glycol can also be used. Examples of humidification and humectants include polyols, glycerol, cetyl alcohol, carbopol 934, ethoxylated castor oil, paraffin oils, lanolin and their derivatives. Silicone compounds such as silicone surfactants such as DC3225C (Dow Corning) and / or silicone emollients, silicone oil (DC-200 Ex-Dow Corning) can also be used. The compositions according to the invention can be prepared for local application to the skin / hair in the form of simple solutions or conventional application or washing products such as lotions, creams, ointments, shampoos and / or aerosol products. All percentages referred to herein and in the appended claims are by weight of the composition unless indicated as c o n t r a r i o. The invention will now be illustrated by means of Examples. The Examples are for illustration only and do not restrict the scope of the invention in any way.
EXAMPLE 1 Demonstrated n_ in vi tro of the improvement in the formation of melanin The influence of a peptide sequence with pl 11.0 on the formation of melanin at pH 5 in an in vi tro system, compared to the pH of the system, was analyzed. melanosomal The test conditions for the formation of melanin under conditions i n vi t r o are as follows.
Test Method The test control mixture contains 5 μmoles of DL-DOPA (Dihydroxy phenyl alanine), 20 nmoles of lysozyme and 3.2 units of tyrosinase in acetate buffer pH 5.0 in a test tube. A unit is defined as the amount of tyrosinase needed to convert one nmol of DOPA in one minute. In the experimental set, 11 nmol of polylysine, a poly amino acid sequence with pl 11.0, were used, in addition to other ingredients as defined in the control. The formed melanin was washed with the acetates regulator, the IN sodium hydroxide was suspended and dissolved by heating the sample at 60 ° C for 5 minutes. The absorbance was measured at 400 nm.
Table 1 Sample Melanin formed A 400
Control 0.120 In the presence of polylysine 0.168 The above results show that the polylysine sequence production of melanin is significantly improved. The invention will now be illustrated by reference to the following example of a cosmetic cream.
The application of the cosmetic cream described in the Comparative Example and Example 2 will show that the product described in Example 2 will be significantly superior in darkening of the skin to that of the Comparative Example. It is therefore possible by means of the present invention to provide a composition for darkening the skin / hair which is reversible and without any side effects. The composition is active during the day and night. The numbers in the table represent percentages of the composition by weight.
E x p e 3 Demonstration in vi trode the improvement of the formation of e_l ariina_ The influence of the sequence of poly-amino acid with pol ig ut to pl 2.5, polyarginine (pl 0.9) or polylysine (pl 11.0) in the formation of melanin at pH 5 in an in vi t ro system, comparable to the pH of the melanosomal system, was analyzed. The test conditions for the formation of melanin under conditions i n vi t r o are normal.
Test method: The test control mixture contains 5 mmoles of DL-DOPA (Dihydroxy phenylalanine), lysozyme 20 nmol and 0.45mg of tyrosinase in acetate buffer pH 5.0 in a test tube. In the experimental set, 18 nmol of the poly glutamate were used, as well as a sequence of po 1 i ami noá ci do with pl 2.5 or polyarginine pl 10.9 or polylysine pl 11.0 in addition to the other ingredients as defined in the control. The formed melanin was washed with the regulator, suspended in IN sodium hydroxide and dissolved by heating the sample at 60 ° C for 5 minutes. The absorbance was measured at 400 nm.
Table 2 Sample Melanin formed A 400
Control 0.120 In the presence of polyglutamate pl 3-4 0.048 In the presence of polylysine pl 11.0 0.168 In the presence of polyarginine pl 10.9 0.182
The above results show that in the presence of the sequence of po 1 i ami no acid with alkaline pl or p > 5.0 the production of melanin is significantly increased while in the presence of the sequence of po 1 i amino acid with pl in the acid range does not achieve a similar improvement in melanin production. Example 4 Demonstration of the improvement of ^. melanin formation _ _ _ Twelve female volunteers were chosen with a level skin tone and no scars / visible hair on the forearms. On the palmar side of the forearm, 1 cm squared sites were marked using a template. A mixture of peptides of molecular weight reaching 14 K daltons, having a pl 11.2 at a concentration of 2% in a suitable vehicle was used. The previous solution contains 0.3 μg of protein / μl and 5ml of it was applied for 10 days. The (vehicle) without treatment and placebo served as control. The sites were graduated by an expert, who was blinded to treatment assignments, on day zero and on the eleventh day. The data presented in table 3 show that even under conditions i n v i vo peptides with a pl > 5.0 darkened the skin significantly compared to the two controls, ie the untreated and the vehicle. The critical difference is 0.12. . - - - -
Registration for the Expert Evaluation: SUBSTANTIALLY CLARIFIED -1.0 SUBSTANTIALLY DARK +1.0
DEFINITELY CLARIFIED -0.75 DEFINITELY DARKLY +0.75
MODERATELY CLARIFIED -0.5 MODERATELY OSCURECIDA +0.5
SLIGHTLY CLARIFIED -0.25 SLIGHTLY DARK +0.25 NO DIFFERENCE 0
Claims (9)
1. Cosmetic composition for darkening the skin and / or hair comprising from 0.1 to 10% by weight of a peptide having an isoelectric point ranging from 6 to 11.
2. Cosmetic composition according to claim 1, which is applied locally to the skin and / or hair.
3. Cosmetic composition according to the rei indication 1 or 2, wherein the peptide has a molecular weight of 200 to 20,000 Da.
4. Cosmetic composition according to any preceding claim wherein the peptide is linked to either: a) a hydrophobic amino acid selected from alanine, isoleucine, leucine, methionine, phenylalanine, valine, proline and tryptophan; or b) an objective molecule or vehicle.
5. Cosmetic composition according to claim 4, wherein the hydrophobic amino acid is tryptophan.
6. Cosmetic composition according to claim 4 or 5 wherein the target molecule is a peptide.
7. Cosmetic composition according to claim 4, wherein the target molecule is a hexapeptide having the primary sequence (I): (I) Asx-Glm-Por-Leu-Leu-Thr
8. Cosmetic composition according to the rei indication 4, wherein the target vehicle is a micelle or inverse micelle.
9. Cosmetic method of skin / hair darkening comprising the local application to the skin / hair of a composition according to any of the preceding expressions.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9801191.9 | 1998-01-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA00007102A true MXPA00007102A (en) | 2001-07-09 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1049450B1 (en) | Skin and hair darkening composition | |
EP0739195B1 (en) | Skin tanning compositions | |
CA2448274C (en) | Composition containing a peptide and a pigment and the use thereof in darkening the skin | |
US7935331B2 (en) | Vanillin polymers for use in darkening the skin | |
AU2009217391A1 (en) | Peptides and the use thereof in darkening the skin | |
KR19980702510A (en) | Cosmetic melanin | |
US20080200396A1 (en) | Peptides or Peptidic Conjugate Derivatives of Msh and the Use Thereof for Cosmetically Fighting Against Canities | |
WO2009051460A2 (en) | Peptide coupled ascorbic acid derivatives | |
US6696417B1 (en) | Skin and hair darkening composition | |
US7081442B2 (en) | Composition containing a peptide and a pigment and the use thereof in darkening the skin | |
WO2017159922A1 (en) | Conjugate of finasteride with peptide | |
EP1584320A1 (en) | Cosmetic preparation containing glycerylamino acid derivative | |
MXPA00007102A (en) | Skin and hair darkening composition | |
EP2523967B1 (en) | Novel anti-ageing peptides modulating survivin and compositions including same | |
CN108129551B (en) | Peptide having skin whitening effect and use thereof | |
WO1999012518A1 (en) | Skin lightening composition | |
EP0714418B1 (en) | Cosmetic melanins | |
KR101308977B1 (en) | Cosmetic composition for skin whitening containing tripeptide of cysteine-methionine | |
EP1507508B1 (en) | Composition containing a peptide and a pigment and the use thereof in darkening the skin | |
KR100385448B1 (en) | Cosmetic for tanning containing brazilin as main component | |
KR20170019670A (en) | Composition for improving wrinkles and elasticity of skin | |
AU2002305718A1 (en) | Composition containing a peptide and a pigment and the use thereof in darkening the skin |